NPPNY
Price
$5.19
Change
-$0.18 (-3.35%)
Updated
Sep 17 closing price
Capitalization
1.53B
OMID
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
Sep 17 closing price
Capitalization
1.77M
26 days until earnings call
Interact to see
Advertisement

NPPNY vs OMID

Header iconNPPNY vs OMID Comparison
Open Charts NPPNY vs OMIDBanner chart's image
Nippon Shinyaku
Price$5.19
Change-$0.18 (-3.35%)
Volume$248
Capitalization1.53B
Omid
Price$0.02
Change-$0.00 (-0.00%)
Volume$962
Capitalization1.77M
NPPNY vs OMID Comparison Chart in %
Loading...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NPPNY vs. OMID commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NPPNY is a Hold and OMID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (NPPNY: $5.19 vs. OMID: $0.02)
Brand notoriety: NPPNY and OMID are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: NPPNY: 20% vs. OMID: 3%
Market capitalization -- NPPNY: $1.53B vs. OMID: $1.77M
NPPNY [@Pharmaceuticals: Generic] is valued at $1.53B. OMID’s [@Pharmaceuticals: Generic] market capitalization is $1.77M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.35B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NPPNY’s FA Score shows that 2 FA rating(s) are green whileOMID’s FA Score has 1 green FA rating(s).

  • NPPNY’s FA Score: 2 green, 3 red.
  • OMID’s FA Score: 1 green, 4 red.
According to our system of comparison, NPPNY is a better buy in the long-term than OMID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NPPNY’s TA Score shows that 4 TA indicator(s) are bullish while OMID’s TA Score has 3 bullish TA indicator(s).

  • NPPNY’s TA Score: 4 bullish, 3 bearish.
  • OMID’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both NPPNY and OMID are a good buy in the short-term.

Price Growth

NPPNY (@Pharmaceuticals: Generic) experienced а -3.33% price change this week, while OMID (@Pharmaceuticals: Generic) price change was -12.57% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +26.39%. For the same industry, the average monthly price growth was +26.40%, and the average quarterly price growth was +60.38%.

Reported Earning Dates

OMID is expected to report earnings on Oct 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+26.39% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NPPNY($1.53B) has a higher market cap than OMID($1.77M). OMID YTD gains are higher at: -7.038 vs. NPPNY (-21.822).
NPPNYOMIDNPPNY / OMID
Capitalization1.53B1.77M86,263%
EBITDA36.5BN/A-
Gain YTD-21.822-7.038310%
P/E Ratio6.33N/A-
Revenue154BN/A-
Total Cash66BN/A-
Total Debt2.55BN/A-
FUNDAMENTALS RATINGS
NPPNY vs OMID: Fundamental Ratings
NPPNY
OMID
OUTLOOK RATING
1..100
3838
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
181
PRICE GROWTH RATING
1..100
7960
P/E GROWTH RATING
1..100
7164
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NPPNY's Valuation (6) in the null industry is significantly better than the same rating for OMID (80). This means that NPPNY’s stock grew significantly faster than OMID’s over the last 12 months.

OMID's Profit vs Risk Rating (95) in the null industry is in the same range as NPPNY (100). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

OMID's SMR Rating (1) in the null industry is in the same range as NPPNY (18). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

OMID's Price Growth Rating (60) in the null industry is in the same range as NPPNY (79). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

OMID's P/E Growth Rating (64) in the null industry is in the same range as NPPNY (71). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NPPNYOMID
RSI
ODDS (%)
Bullish Trend 2 days ago
33%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
33%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 30 days ago
88%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
37%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RKDA3.510.08
+2.34%
Arcadia Biosciences
TARS51.691.09
+2.15%
Tarsus Pharmaceuticals
TATT39.310.51
+1.33%
TAT Technologies Ltd
STN109.44-0.75
-0.68%
Stantec
XBIT2.64-0.05
-1.86%
XBiotech

NPPNY and

Correlation & Price change

A.I.dvisor tells us that NPPNY and MEDIF have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NPPNY and MEDIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NPPNY
1D Price
Change %
NPPNY100%
-3.33%
MEDIF - NPPNY
11%
Poorly correlated
+4.55%
OVATF - NPPNY
10%
Poorly correlated
N/A
OMID - NPPNY
3%
Poorly correlated
-2.86%
OILFF - NPPNY
-1%
Poorly correlated
+4.13%
MKGAF - NPPNY
-1%
Poorly correlated
+0.42%
More

OMID and

Correlation & Price change

A.I.dvisor tells us that OMID and OWPC have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OMID and OWPC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMID
1D Price
Change %
OMID100%
-2.86%
OWPC - OMID
10%
Poorly correlated
-7.21%
OILFF - OMID
9%
Poorly correlated
+4.13%
RGEDF - OMID
6%
Poorly correlated
N/A
RAFA - OMID
3%
Poorly correlated
+6.70%
PHCUF - OMID
3%
Poorly correlated
N/A
More